| CPH 82. | |
| | |
MedLine Citation:
|
PMID: 14498767 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CPH 82 [Reumacon] is a purified semi-synthetic lignan glycoside derivative of the medicinal herb Podophyllum emodi which inhibits microtubules. It has been jointly developed by the Swedish company Conpharm and the Swiss company Analytecon SA. It has potential for the treatment of rheumatoid arthritis. The Swedish company Meda is licencing the drug and has taken over responsibility from Conpharm for development and documentation. Meda has obtained exclusive marketing rights for Reumacon worldwide, except in China and some other Asian countries. Meda plans to form partnerships with other companies in the marketing of Reumacon. |
| | |
Authors:
|
- |
Related Documents
:
|
15537407 - Specific training in clinical forensic medicine is useful to acem trainees. 834407 - The management of midtrimester abortion failures by vaginal evacuation. 10127977 - Practice parameters benefit all. patient management strategies improve outcomes for pat... 12014567 - Case i: managing people--the case of the frustrated faculty member. 10194577 - Doctors' narratives in balint groups. 12081637 - The effects on gp prescribing of joining a commissioning group. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy Volume: 17 ISSN: 1173-8804 ISO Abbreviation: BioDrugs Publication Date: 2003 |
Date Detail:
|
Created Date: 2003-09-22 Completed Date: 2004-04-15 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 9705305 Medline TA: BioDrugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 373-4 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Arthritis, Rheumatoid / drug therapy Clinical Trials as Topic Glycosides / administration & dosage, adverse effects, therapeutic use* Humans Lignans / administration & dosage, adverse effects, therapeutic use* Paclitaxel Podophyllotoxin |
| Chemical | |
Reg. No./Substance:
|
0/CPH 82; 0/Glycosides; 0/Lignans; 33069-62-4/Paclitaxel; 518-28-5/Podophyllotoxin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Atlizumab: anti-IL-6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chug...
Next Document: Somatomedin-1 binding protein-3: insulin-like growth factor-1 binding protein-3, insulin-like growth...